Mergers, acquisitions, partnerships, deals
Afya and Yduqs signed a merger agreement on September 23, 2026, creating a combined group with R$9.4 billion in revenue and roughly 5,900 annual medical-school seats, subject to antitrust review …
Mergers, acquisitions, partnerships, deals
Afya and Yduqs signed a merger agreement on September 23, 2026, creating a combined group with R$9.4 billion in revenue and roughly 5,900 annual medical-school seats, subject to antitrust review …
Bio-Techne shareholders have approved the $11.3 billion acquisition by Merck KGaA of Darmstadt, Germany, clearing a key procedural milestone as the deal moves toward a close expected by late 2026 …
Telix Pharmaceuticals agrees to acquire ITM Isotope Technologies Munich for up to $2.35 billion, securing isotope supply and adding ITM-11, a Phase 3 neuroendocrine tumour candidate that received an FDA …
AbbVie has completed its $10.9 billion acquisition of Apogee Therapeutics, adding zumilokibart — a long-acting interleukin-13 antibody positioned against Dupixent — to its immunology portfolio.
Eli Lilly agreed to acquire Merida Biosciences for up to $2.9 billion, adding a precision antibody-targeting platform to its immunology pipeline as the company’s 2026 acquisition total surpasses $31 billion.
Brazil’s securities regulator has ordered a tender offer for Oncoclínicas shares, with analysts estimating the total outlay at R$ 12–14 billion — roughly double initial projections — as a parallel …
You must be logged in to post a comment.